BioPorto (CPSE:BIOPOR) - Cotización, noticias y análisis

Resumen de acción BIOPOR

BioPorto A/S, empresa de diagnóstico in vitro, suministra herramientas de biomarcadores y anticuerpos para la investigación clínica en Europa, Norteamérica, Asia y a escala internacional. Saber más

Análisis fundamental de BIOPOR
Puntuación del snowflake
Valoración	0/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 29.18%

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 35% al año durante los próximos 3 años

No tiene ingresos significativos (DKK34M)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

+ 2 riesgos adicionales

Competidores de BioPorto A/S

Bavarian Nordic

CPSE:BAVA

DKK 14.6b

Genmab

CPSE:GMAB

DKK 93.0b

TCM Biotech International

TPEX:4169

NT$3.5b

Protalix BioTherapeutics

NYSEAM:PLX

US$103.0m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de BioPorto
Precios históricos de las acciones
Precio actual de la acción	DKK 1.62
Máximo en las últimas 52 semanas	DKK 3.85
Mínimo de 52 semanas	DKK 1.21
Beta	1.15
1Cambio en 1 mes	-13.26%
Variación en 3 meses	-24.21%
Cambio de 1 año	-33.80%
3Variación en 3 años	-49.23%
Variación en 5 años	-48.26%
Variación desde la OPV	-99.29%

Noticias y actualizaciones recientes

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Oct 22

Recent updates

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Oct 16

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

May 28

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

Mar 01

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

Jan 24

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

Dec 20

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

Nov 23

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Nov 21

Rentabilidad de los accionistas

	BIOPOR	DK Biotechs	Mercado DK
7D	-7.4%	-14.0%	-6.0%
1Y	-33.8%	-11.5%	4.2%

Rentabilidad vs. Industria: Los resultados de BIOPOR fueron inferiores a los de la industria Danish Biotechs, que obtuvo un rendimiento del -11.5% el año pasado.

Rentabilidad vs. Mercado: BIOPOR obtuvo unos resultados inferiores a los del mercado Danish, que fueron del 4.2% el año pasado.

Volatilidad de los precios

Is BIOPOR's price volatile compared to industry and market?
BIOPOR volatility
BIOPOR Average Weekly Movement	6.2%
Biotechs Industry Average Movement	7.9%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.4%
10% least volatile stocks in DK Market	2.5%

Precio estable de las acciones: El precio de las acciones de BIOPOR ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BIOPOR(6%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Danish.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1917	27	Peter Eriksen	bioporto.com

BioPorto A/S, empresa de diagnóstico in vitro, suministra herramientas de biomarcadores y anticuerpos para la investigación clínica en Europa, Norteamérica, Asia e internacionalmente. Ofrece la prueba de la lipocalina asociada a la gelatinasa de neutrófilos, un inmunoensayo turbidimétrico cuantitativo mejorado por partículas diseñado para funcionar en analizadores de química clínica automatizados; anticuerpos monoclonales para investigación científica, farmacéutica y clínica; y kits de ensayo inmunoenzimático, así como un dispositivo genérico de ensayo rápido para ensayos de flujo lateral personalizados. BioPorto A/S se constituyó en 1917 y tiene su sede en Hellerup (Dinamarca).

Resumen de fundamentos de BioPorto A/S

¿Cómo se comparan los beneficios e ingresos de BioPorto con su capitalización de mercado?
Estadísticas fundamentales de BIOPOR
Capitalización bursátil	DKK 696.90m
Beneficios(TTM)	-DKK 50.01m
Ingresos (TTM)	DKK 33.83m

20.6x

Ratio precio-ventas (PS)

-13.9x

Ratio precio-beneficio (PE)

¿Está BIOPOR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BIOPOR
Ingresos	DKK 33.83m
Coste de los ingresos	DKK 9.55m
Beneficio bruto	DKK 24.28m
Otros gastos	DKK 74.29m
Beneficios	-DKK 50.01m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.12
Margen bruto	71.76%
Margen de beneficio neto	-147.84%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado BIOPOR a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción BIOPOR

Recompensas

Análisis de riesgos

Competidores de BioPorto A/S

CPSE:BAVA

DKK 14.6b

CPSE:GMAB

DKK 93.0b

TPEX:4169

NT$3.5b

NYSEAM:PLX

US$103.0m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New minor risk - Market cap size

Bioporto A/S Maintains Revenue Guidance for the Year 2024

BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Consensus EPS estimates fall by 80%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

New minor risk - Market cap size

Bioporto A/S Maintains Revenue Guidance for the Year 2024

BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Consensus EPS estimates fall by 80%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioporto A/S Affirms Earnings Guidance for 2024

New major risk - Share price stability

New minor risk - Shareholder dilution

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

BioPorto A/S Announces CEO Changes

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

New major risk - Share price stability

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Consensus estimates of losses per share improve by 16%

New major risk - Financial position

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioPorto A/S Maintains Earnings Guidance for the Year 2023

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

BioPorto A/S, Annual General Meeting, Apr 27, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Price target decreased to kr.3.50

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)